Akaal Pharma wins Japanese patent for lead S1P1 drug candidates

By AI, Created 6:01 PM UTC, June 02, 2026, /AGP/ – Akaal Pharma has secured a Japanese patent for its lead clinical-stage S1P1 agonists, TAKP-119 and OAKP-11, expanding protection in a major pharmaceutical market. The grant supports the company’s plans to advance treatments for inflammatory skin disease, itch and pain while it pursues partnering and licensing deals.

Why it matters: - The Japanese patent strengthens Akaal Pharma’s intellectual property position around TAKP-119 and OAKP-11, two clinical-stage S1P1 agonists. - Broader patent coverage can support development, partnering and eventual commercialization in a large pharmaceutical market. - The patent adds protection across formulations, delivery methods and therapeutic uses tied to the company’s lead assets.

What happened: - Akaal Pharma Pty Ltd announced the grant of Japan Patent No. 7850669 for “S1P Receptor Modulators.” - The patent covers the company’s lead clinical-stage Sphingosine-1-Phosphate receptor subtype-1 agonists, TAKP-119 and OAKP-11. - The announcement came from Shepparton, Victoria, Australia, on June 2, 2026.

The details: - The Japanese patent provides broad protection across multiple formulations, delivery methods and therapeutic applications. - Akaal Pharma is developing TAKP-119 and OAKP-11 for inflammatory skin diseases, pruritus and pain-related conditions. - The candidates have shown efficacy in clinical and preclinical settings across inflammatory dermatology indications, including psoriasis and atopic dermatitis. - The company says the assets also have broader potential in itch and neuropathic pain indications. - CEO Dr Tony Rajic said the patent grant marks a significant milestone and confirms the long-term value of the clinical drug candidates. - Akaal Pharma describes TAKP-119 and OAKP-11 as proprietary clinical-stage S1P1 modulators.

Between the lines: - The patent grant signals a push to build a defensible global patent estate around the company’s core pipeline. - Stronger IP can make a biotech company more attractive to potential partners and licensees. - Akaal Pharma is framing the S1P class as a platform with possible use across several high-unmet-need indications, not just one disease area.

What’s next: - Akaal Pharma plans to continue pursuing global partnering, co-development and licensing opportunities. - The company will keep advancing its clinical-stage pipeline toward development and possible commercialization. - The patent position may help support future deal discussions and program expansion.

The bottom line: - Akaal Pharma has expanded its patent protection in Japan as it works to turn two lead S1P1 programs into broader clinical and commercial opportunities.